167 related articles for article (PubMed ID: 17907374)
1. Bisphosphonates and the dental patient: Part 2.
Zak M; Spina AM; Spinazze RP; Perkinson WL; Spinazze DJ
Compend Contin Educ Dent; 2007 Sep; 28(9):510-5; quiz 516, 528. PubMed ID: 17907374
[TBL] [Abstract][Full Text] [Related]
2. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment.
; Khosla S; Burr D; Cauley J; Dempster DW; Ebeling PR; Felsenberg D; Gagel RF; Gilsanz V; Guise T; Koka S; McCauley LK; McGowan J; McKee MD; Mohla S; Pendrys DG; Raisz LG; Ruggiero SL; Shafer DM; Shum L; Silverman SL; Van Poznak CH; Watts N; Woo SB; Shane E
J Oral Maxillofac Surg; 2008 Jun; 66(6):1320-1; author reply 1321-2. PubMed ID: 18486811
[No Abstract] [Full Text] [Related]
3. Bisphosphonate-induced osteonecrosis: dental considerations.
Gross HB
Compend Contin Educ Dent; 2008 Mar; 29(2):112-3. PubMed ID: 18429426
[No Abstract] [Full Text] [Related]
4. Management of bisphosphonate-induced osteonecrosis of the jaw.
Schilling J
Northwest Dent; 2008; 87(3):34-5, 37-8, 40. PubMed ID: 18663869
[TBL] [Abstract][Full Text] [Related]
5. Bisphosphonates and bisphosphonate induced osteonecrosis.
Sawatari Y; Marx RE
Oral Maxillofac Surg Clin North Am; 2007 Nov; 19(4):487-98, v-vi. PubMed ID: 18088900
[TBL] [Abstract][Full Text] [Related]
6. Serologic bone markers for predicting development of osteonecrosis of the jaw in patients receiving bisphosphonates.
Lazarovici TS; Mesilaty-Gross S; Vered I; Pariente C; Kanety H; Givol N; Yahalom R; Taicher S; Yarom N
J Oral Maxillofac Surg; 2010 Sep; 68(9):2241-7. PubMed ID: 20728033
[TBL] [Abstract][Full Text] [Related]
7. Osteonecrosis of the jaw and biomarkers: what do we tell our patients?
Koka S
Int J Oral Maxillofac Implants; 2008; 23(2):179-80. PubMed ID: 18548914
[No Abstract] [Full Text] [Related]
8. Editorial opinion versus real data and knowledge of the literature.
Marx RE
Int J Oral Maxillofac Implants; 2008; 23(4):587-8. PubMed ID: 18807554
[No Abstract] [Full Text] [Related]
9. Serum CTX testing.
Schwartz HC
J Oral Maxillofac Surg; 2008 Jun; 66(6):1319-20; author reply 1320. PubMed ID: 18486810
[No Abstract] [Full Text] [Related]
10. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment.
Marx RE; Cillo JE; Ulloa JJ
J Oral Maxillofac Surg; 2007 Dec; 65(12):2397-410. PubMed ID: 18022461
[TBL] [Abstract][Full Text] [Related]
11. Bisphosphonates and bone...what have we learned?
Guttenberg SA
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Dec; 106(6):769-72. PubMed ID: 18835534
[No Abstract] [Full Text] [Related]
12. CTX biochemical marker of bone metabolism. Is it a reliable predictor of bisphosphonate-associated osteonecrosis of the jaws after surgery? Part I: biological concepts with a review of the literature.
Lee CY; Suzuki JB
Implant Dent; 2009 Dec; 18(6):492-500. PubMed ID: 20009603
[TBL] [Abstract][Full Text] [Related]
13. CTX and its role in managing patients exposed to oral bisphosphonates.
Dodson TB
J Oral Maxillofac Surg; 2010 Feb; 68(2):487-8; author reply 488-9. PubMed ID: 20116729
[No Abstract] [Full Text] [Related]
14. Bisphosphonates--what the dentist needs to know: practical considerations.
Fantasia JE
J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):53-60. PubMed ID: 19371815
[No Abstract] [Full Text] [Related]
15. Bisphosphonates, phossy jaw, and bisphosphonate-related osteonecrosis of the jaw.
Lewis DM
J Okla Dent Assoc; 2011; 102(5):36-9. PubMed ID: 21874699
[No Abstract] [Full Text] [Related]
16. Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates.
King AE; Umland EM
Pharmacotherapy; 2008 May; 28(5):667-77. PubMed ID: 18447663
[TBL] [Abstract][Full Text] [Related]
17. Osteonecrosis in the jaws of patients who are using oral biphosphonates to treat osteoporosis.
Dello Russo NM; Jeffcoat MK; Marx RE; Fugazzotto P
Int J Oral Maxillofac Implants; 2007; 22(1):146-53. PubMed ID: 17340909
[No Abstract] [Full Text] [Related]
18. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
[TBL] [Abstract][Full Text] [Related]
19. A review of the clinical implications of bisphosphonates in dentistry.
Borromeo GL; Tsao CE; Darby IB; Ebeling PR
Aust Dent J; 2011 Mar; 56(1):2-9. PubMed ID: 21332734
[TBL] [Abstract][Full Text] [Related]
20. [Osteonecrosis of the jaws: a secondary effect of bisphosphonates].
Schortinghuis J; Meijndert L; De Visscher JG; Witjes MJ
Rev Belge Med Dent (1984); 2007; 62(4):168-75. PubMed ID: 18506991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
